In our recent study, we uncovered that CHD1 loss impaired the in vitro and in vivo efficacy of Aurora kinase inhibitors, while high expression of CHD1 is associated with increased sensitivity in a pan-cancer manner (26). The gene discussed is CHD1; the disease is cancer.